ArticleMolecular oncology2016
Plasma protein profiling in a stage defined pancreatic cancer cohort - Implications for early diagnosis.
Article in Molecular oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- Plasma Proteomics Identifies Potential Pancreatic Cancer Risk Indicators in Type 2 Diabetes.Pancreas · 2026Article
- Identification of novel plasma proteins as promising noninvasive biomarker for early diagnosis and surveillance of pancreatic ductal adenocarcinoma.Journal of gastroenterology · 2025Article
- Incorporation of explainable artificial intelligence in ensemble machine learning-driven pancreatic cancer diagnosis.Scientific reports · 2025Article
- Machine learning-optimized metabolic biomarker panel for precision screening of early-stage pancreatic cancer in new-onset diabetes.Frontiers in endocrinology · 2025Article
- N-glycan biosignatures as a potential diagnostic biomarker for early-stage pancreatic cancer.World journal of gastrointestinal oncology · 2024Article
- Multiplexed analysis of EV reveals specific biomarker composition with diagnostic impact.Nature communications · 2023Article
- Identification of a serum biomarker signature associated with metastatic prostate cancer.Proteomics. Clinical applications · 2021Article
- Article
- Systemic Proteome Alterations Linked to Early Stage Pancreatic Cancer in Diabetic Patients.Cancers · 2020Article
- Familial Pancreatic Cancer: Current Perspectives.Cancer management and research · 2020Review
- The Relevance of Mass Spectrometry Analysis for Personalized Medicine through Its Successful Application in Cancer "Omics".International journal of molecular sciences · 2019Review
- A review of lifestyle, metabolic risk factors, and blood-based biomarkers for early diagnosis of pancreatic ductal adenocarcinoma.Journal of gastroenterology and hepatology · 2019Review
- Article
- Circulating Biomarkers to Identify Patients With Resectable Pancreatic Cancer.Journal of the National Cancer Institute · 2017Article
- Implementing liquid biopsies into clinical decision making for cancer immunotherapy.Oncotarget · 2017Review
- Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer.Nature reviews. Cancer · 2017Review
- Plasma protein profiling in a stage defined pancreatic cancer cohort - Implications for early diagnosis.Molecular oncology · 2016Article
- Biomarkers in pancreatic adenocarcinoma: current perspectives.OncoTargets and therapy · 2016Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a disease where detection preceding clinical symptoms significantly increases the life expectancy of patients. In this study, a recombinant antibody microarray platform was used to analyze 213 Chinese plasma samples from PDAC patients and normal control (NC) individuals. The cohort was stratified according to disease stage, i.e. resectable disease (stage I/II), locally advanced (stage III) and metastatic disease (stage IV). Support vector machine analysis showed that all PDAC stages could be discriminated from controls and that the accuracy increased with disease progression, from stage I to IV. Patients with stage I/II PDAC could be discriminated from NC with high accuracy based on a plasma protein signature, indicating a possibility for early diagnosis and increased detection rate of surgically resectable tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.